Turnstone Biologics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Turnstone Biologics Corp
Access all reports
Turnstone Biologics Corp is a clinical-stage biotechnology company engaged in developing innovative therapies for patients with solid tumors. Their work is centered around the development of tumor infiltrating lymphocytes (TIL) therapies, with a specific focus on selecting and expanding potent tumor-reactive T cells to address the limitations of bulk TILs. Their pipeline includes TIDAL-01 and TIDAL-02, with TIDAL-01 being their lead selected TIL product candidate. This candidate utilizes an unbiased identification and functional screening process to isolate and expand a broad range of tumor-reactive TILs from a patient's tumor. The company is headquartered in La Jolla, California, and its shares are listed on the Nasdaq under the symbol TSBX.
Key slides for Turnstone Biologics Corp
BofA Securities 2024 Health Care Conference
Turnstone Biologics Corp
BofA Securities 2024 Health Care Conference
Turnstone Biologics Corp
Latest articles
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
TSBX
Country
🇺🇸 United States